Verastem Oncology
Biotechnology ResearchMassachusetts, United States51-200 Employees
Verastem Oncology is a biotechnology company focused on developing and commercializing medicines for cancers driven by the RAS/MAPK signaling pathway. Its pipeline is centered on small molecule therapies designed to interrupt critical signaling networks that support cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. The company is headquartered in Needham Heights, Massachusetts, and emphasizes building a diverse team to pursue treatments addressing high unmet medical needs in this cancer subset. The company's work targets patients diagnosed with RAS/MAPK pathway-driven cancers, with clinicians and other healthcare providers as the primary stakeholders involved in care decisions. In May 2026, Verastem launched AVMAPKI FAKZYNJA CO-PACK therapy, while continuing development of its oral KRAS G12D inhibitor candidate, VS-7375. It has also engaged in patient-focused collaborations, including the launch of the LGSOC Resource Guide in partnership with the STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries.
1-888-653-2347 
support@leadiq.com 
